tiprankstipranks
Edgewise Therapeutics, Inc. (EWTX)
NASDAQ:EWTX
US Market
EWTX
Edgewise Therapeutics
RESEARCH TOOLSreports
Want to see EWTX full AI Analyst Report?

Edgewise Therapeutics (EWTX) Stock News & Sentiment

419 Followers
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
Premium
Company Announcements
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
2M ago
EWTX
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
Premium
Company Announcements
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
3M ago
EWTX
EWTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
EWTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
EWTX
Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
Premium
Ratings
Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
5M ago
EWTX
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
Premium
Ratings
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
5M ago
EWTX
Prolonged Safety Uncertainty and Eroding Differentiation Keep EDG-7500 at Hold
Premium
Ratings
Prolonged Safety Uncertainty and Eroding Differentiation Keep EDG-7500 at Hold
5M ago
EWTX
Edgewise Therapeutics Appoints Christopher Martin to Board
Premium
Company Announcements
Edgewise Therapeutics Appoints Christopher Martin to Board
6M ago
8K
EWTX
More EWTX News >

EWTX News on the Web

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter | The Motley Fool
Motley Fool
Neutral
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally | The Motley Fool
Motley Fool
Neutral
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More | The Motley Fool
Motley Fool
Neutral
Goldman Sachs Sticks to Its Hold Rating for Edgewise Therapeutics (EWTX)
TipRanks News
Bearish
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks News
Neutral
Stifel Nicolaus Remains a Hold on Edgewise Therapeutics (EWTX)
TipRanks News
Bearish
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks News
Neutral
Edgewise Therapeutics (EWTX) Receives a Buy from Evercore ISI
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
EWTX
Sector Average
Media Buzz
This Week5 articles
Weekly Average6 articles
News Sentiment
This Week99%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EWTX’s Media Buzz Sentiment?
5 articles about EWTX were published this week. In an average week, 6 articles are published.
    What is EWTX’s weekly average amount of articles?
    In an average week, 6 articles about EWTX are published.
      What is EWTX’s News Sentiment?
      99% of articles about EWTX were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        SBFMSunshine Biopharma
        Showing the stocks with the most bullish news sentiment over the past week